Clinical Infectious Diseases Submission Guide: Scope, Format & Tips

CID focuses on four core areas that drive editorial decisions. Understanding these helps you frame your research correctly.

• Antimicrobial resistance research dominates accepted papers. This includes resistance mechanisms, treatment outcomes for resistant infections, and stewardship interventions. Papers need clinical data showing how resistance affects patient outcomes, not just laboratory susceptibility patterns.

• Immunocompromised host infections represent another major category. Transplant recipients, cancer patients, HIV-positive individuals, and immunosuppressed populations. Editors want studies showing diagnostic approaches, treatment efficacy, or prevention strategies with measurable clinical endpoints.

• Emerging infections and outbreak investigations get priority during health emergencies but need rigorous epidemiological methods year-round. Case series work if they include systematic data collection and statistical analysis. Single case reports rarely make it past desk review unless they demonstrate completely novel pathogens or treatment approaches.

• Treatment outcomes and clinical trials anchor the journal's clinical focus. This includes antibiotic efficacy studies, treatment duration optimization, and comparative effectiveness research. Editors expect adequate sample sizes, appropriate controls, and clinically meaningful endpoints.

Article types break into Clinical Research (full-length studies with complete methodology) and Brief Reports (focused findings under 2,000 words). Both require the same rigor in clinical data and patient outcomes documentation.

The journal doesn't publish basic microbiology, in vitro studies without clinical correlation, or case reports describing standard care. If your research doesn't directly inform clinical decision-making, consider journals like Antimicrobial Agents and Chemotherapy or Journal of Clinical Microbiology instead.

CID editors read cover letters during initial triage. They're looking for clinical relevance and patient impact, not methodology details.

• First paragraph: State your main clinical finding and why it matters for infectious disease practice. "We report treatment outcomes for 150 patients with carbapenem-resistant Enterobacteriaceae infections, showing 28-day mortality reduction with combination therapy versus monotherapy" works better than "We conducted a retrospective cohort study of antimicrobial resistance."

• Clinical significance statement: Explain how your findings change clinical decision-making. Do you provide new diagnostic criteria? Treatment recommendations? Prevention strategies? Editors want concrete clinical applications, not theoretical implications.

• Patient outcomes emphasis: Quantify the patient impact. Mortality reduction, length of stay changes, symptom resolution times, or quality of life improvements. CID editors prioritize research that measurably improves patient care over studies that advance scientific knowledge without clear clinical benefit.

• Journal fit justification: Briefly explain why CID is the right venue. Reference specific CID papers from the past year that relate to your work. This shows you understand the journal's scope and recent editorial priorities.

Don't summarize your methods or results - editors can read your abstract. Don't claim your work is "novel" or "first-of-its-kind" - let the data speak. Keep the total length under 300 words. Longer cover letters suggest unclear thinking about your paper's main message.

Desk rejections often happen early, so understanding why papers fail at triage saves time and helps you pick the right journal faster.

• Basic microbiology without clinical correlation tops the rejection list. Laboratory studies showing antimicrobial susceptibility patterns, biofilm formation, or resistance mechanisms get rejected unless they include clinical outcomes data. Editors want to know how your laboratory findings affect patient care, not just what happens in the petri dish.

• Inadequate patient cohorts kill otherwise solid studies. Case series with fewer than 20 patients rarely survive peer review unless they describe completely novel infections or treatments. Retrospective cohorts need adequate statistical power for their primary endpoints. If your study can't detect clinically meaningful differences, editors will reject it before peer review.

• Missing outcome data represents a fundamental flaw editors catch quickly. Papers describing diagnostic approaches without sensitivity/specificity data, treatment studies without clinical response rates, or prevention interventions without infection rate comparisons don't meet CID's clinical focus requirements.

• Poor statistical analysis becomes apparent during editorial review. Multiple comparisons without correction, inappropriate statistical tests for the data type, or underpowered analyses for the stated objectives result in rejection. CID editors expect statistical rigor matching the clinical importance of your findings.

• Lack of clinical context affects papers with solid data but unclear clinical implications. Your discussion needs to explain how clinicians should use your findings. What changes in practice does your research support? When should clinicians apply your diagnostic criteria or treatment recommendations?

Studies that describe standard care without novel insights, case reports of common infections, or research primarily interesting to basic scientists rather than clinicians don't fit CID's mission. Check these warning signs before submitting to avoid predictable rejections.

CID's review process runs 90-120 days for most submissions, with desk rejections happening much faster.

• Week 1-2: Editorial triage determines if your paper goes to peer review or gets desk rejected. Editors check scope fit, clinical relevance, and methodological adequacy. About half of submissions get desk rejected at this stage.

• Week 2-4: Papers passing triage get assigned to associate editors who select peer reviewers. CID typically uses 2-3 reviewers for Clinical Research articles, 2 reviewers for Brief Reports.

• Week 4-12: Peer review period. Reviewers get 3-4 weeks to complete reviews, but extensions are common. The editorial office sends reminder notices but can't force faster reviews.

• Week 12-16: Editorial decision based on reviewer comments and associate editor recommendations. Decisions include accept (rare on first submission), minor revisions, major revisions, or reject.

• Revision timeline: You get 2-3 months for major revisions, 1 month for minor revisions. Extensions are available if you request before the deadline. Revised papers typically get faster second reviews.

The process moves slower than emergency medicine or cardiology journals but faster than basic science publications. Don't expect decisions in 30-60 days unless your paper gets desk rejected.

Several scenarios suggest you should consider alternative journals before submitting to CID.

• Basic science focus: If your research emphasizes molecular mechanisms, in vitro studies, or antimicrobial development without clinical data, target journals like Antimicrobial Agents and Chemotherapy or Journal of Antimicrobial Chemotherapy instead.

• Small case series: Studies with fewer than 15-20 patients work better at specialty journals. Consider Open Forum Infectious Diseases for case series that don't meet CID's clinical significance threshold but still contribute to the literature.

• Outbreak investigations: Local outbreak reports without broader epidemiological insights fit better at regional journals or Morbidity and Mortality Weekly Report. CID wants outbreak studies with generalizable prevention or control strategies.

• Alternative high-impact options: Lancet Infectious Diseases may be a better fit for exceptional clinical trials or broader epidemiological work. JAMA Infectious Diseases may suit papers with especially wide clinical implications or policy relevance. Both are more selective and usually demand a bigger top-line story.

• Specialty-specific alternatives: American Journal of Respiratory and Critical Care Medicine for respiratory infections, Clinical Gastroenterology and Hepatology for GI infections, or Transplant Infectious Disease for transplant-related infections. These journals offer specialized audiences and relevant editorial expertise.

Our journal selection guide helps you match your research with the right publication based on scope, audience, and editorial expectations.

Before you upload, run your manuscript through a CID submission readiness check to catch the issues editors filter for on first read.

In our pre-submission review work with manuscripts targeting Clinical Infectious Diseases, three patterns generate the most consistent desk rejections among the papers we analyze.

In our experience, roughly 35% of desk rejections at Clinical Infectious Diseases trace to scope or framing problems that prevent the paper from competing in this venue. In our experience, roughly 25% involve insufficient methodological rigor or missing validation evidence. In our experience, roughly 20% arise from a novelty claim that outpaces the supporting data.

• Laboratory data submitted without clinical outcomes. CID's author guidelines state that the journal publishes "clinical infectious disease studies" focused on "diagnosis, treatment, prevention, and management." The failure pattern is a manuscript reporting antimicrobial susceptibility patterns, biofilm formation data, or resistance mechanism characterization without connecting the findings to measurable patient outcomes. Editors return these before peer review with a consistent note: the work may be scientifically sound but does not meet CID's clinical scope. In vitro MIC data without clinical breakpoints, infection outcomes, or treatment response rates is not a CID paper, regardless of the organism's clinical importance.

• Underpowered cohorts where the primary endpoint is underdetermined. CID reviewers consistently flag studies where the stated primary endpoint requires a sample size the manuscript cannot support. A retrospective study of 18 patients reporting mortality as the primary outcome and finding no significant difference is a statistical power problem, not a clinical finding. We observe this pattern frequently in case series from single tertiary centers studying rare infections. The paper may describe genuine clinical experience, but CID's editorial standard for outcomes-driven research requires demonstrating an effect size or ruling one out with appropriate confidence. SciRev author-reported data confirms CID's median first decision at approximately 4-6 weeks, with desk rejections typically at the 1-2 week mark.

Clarivate JCR 2024 bibliometric data provides additional benchmarks when evaluating journal fit.

• Clinical significance overstated relative to study design. CID editors apply the "practice-change test": does the finding change what a clinician does tomorrow? The failure pattern is a manuscript with an observational design that concludes by recommending a specific treatment change or diagnostic approach. Retrospective cohorts cannot establish causation, and reviewers flag conclusions that exceed the design's inferential reach. Papers that present adjusted odds ratios from observational data and conclude with "these findings suggest that clinicians should prefer X" rather than "these findings support further investigation of X" generate major revision requests or rejections for overclaiming. A CID submission readiness check can identify scope framing and statistical adequacy issues before the submission window.

Looking for more submission guidance? Our journal cover letter examples include infectious disease templates, while choosing the right journal guide compares CID with alternative infectious disease publications. Don't submit until you've checked our paper readiness assessment.

Need expert feedback before submitting to Clinical Infectious Diseases? Manusights provides pre-submission manuscript reviews that identify common rejection risks and help position your research for acceptance at competitive journals.